Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.5357
+0.0068 (1.29%)
Nov 11, 2026, 10:57 AM EST - Market open
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
475.48K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Jaguar Health | 27.82M |
| Scinai Immunotherapeutics | 3.07M |
| SciSparc | 679.00K |
| Decoy Therapeutics | 227.63K |
| Biodexa Pharmaceuticals | 104.90K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
VBIO News
- 3 hours ago - Valion Bio to discuss entolimod at RW Baird’s National Security Conference - TheFly
- 12 days ago - Valion Bio says AFRRI to evaluate therapeutic efficacy of entolimod - TheFly
- 14 days ago - Valion Bio announces data from NIAID, RNCP-funded safety study of Entolimod - TheFly
- 16 days ago - Valion Bio receives unsolicited acquisition interest in Velocity Bioworks - TheFly
- 21 days ago - Valion Bio unveils agenda to accelerate clinical pipeline, shareholder value - TheFly
- 21 days ago - Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value - Accesswire
- 25 days ago - Valion Bio files to sell 3.95M shares of common stock for holders - TheFly
- 26 days ago - Valion Bio Proxy statement: Proxy filing - Filings